AR081828A1 - Compuestos de biguanida y su uso para el tratamiento del cancer - Google Patents
Compuestos de biguanida y su uso para el tratamiento del cancerInfo
- Publication number
- AR081828A1 AR081828A1 ARP110101794A ARP110101794A AR081828A1 AR 081828 A1 AR081828 A1 AR 081828A1 AR P110101794 A ARP110101794 A AR P110101794A AR P110101794 A ARP110101794 A AR P110101794A AR 081828 A1 AR081828 A1 AR 081828A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- coor11
- replaced
- hal
- atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Compuesto de la fórmula (1), en donde R1, R2 cada uno, de modo independiente entre sí, denota H, A, Alk, (CH2)nAr, (CH2)nCyc o (CH2)nHet; R1 y R2 juntos también denotan una cadena de alquileno que tiene 2, 3, 4, 5 ó 6 átomos de C, en donde un grupo CH2 puede estar reemplazado por O, S, SO, SO2, NH, NR8, NCOR8 o NCOOR8, y en donde la cadena de alquileno no está sustituida o está mono-, di- o trisustituida con Hal, A, OR11, N(R11)2, NO2, CN, fenilo, =O, CON(R11)2, NR11COA, NR11CON(R11)2, NR11SO2A, COR11, SO2N(R11)2, S(O)mA, -[C(R11)2]n-COOR11 y/u -O[C(R11)2]o-COOR11; A denota alquilo C1-10 no ramificado o ramificado, en donde uno, dos o tres grupos CH y/o CH2 pueden estar reemplazados por O, S, SO, SO2, NH, NR8 y/o con grupos -CH=CH- y/o, además, 1 - 5 átomos de H pueden estar reemplazados por F, Cl, Br y/o R7; Cyc es cicloalquilo C3-7; Alk denota alquenilo C2-6 o alquinilo C2-6; R7 denota COOR9, CONR9R10, NR9R10, NHCOR9, NHCOOR9 u OR9; R8 denota cicloalquilo C3-7, cicloalquilalquileno C4-10, Alk o alquilo C1-6 no ramificado o ramificado; R9, R10 cada uno, de modo independiente entre sí, denota H o alquilo C1-6, en donde 1 - 3 grupos CH2 pueden estar reemplazados por O, S, SO, SO2, NH, NMe o NEt y/o, además, 1 - 5 átomos de H pueden estar reemplazados por F y/o Cl; Ar denota fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido con Hal, A, OR11, N(R11)2, NO2, CN, fenilo, CON(R11)2, NR11COA, NR11CON(R11)2, NR11SO2A, COR11, SO2N(R11)2, S(O)mA, -[C(R11)2]n-COOR11 y/u -O[C(R11)2]o-COOR11; Het denota un heterociclo saturado, insaturado o aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede estar mono-, di- o trisustituido con Hal, A, OR11, N(R11)2, NO2, CN, COOR11, CON(R11)2, NR11COA, NR11SO2A, COR11, SO2NR11, S(O)mA, =S, =NR11 y/u =O (oxígeno del carbonilo); R11 denota H o A; Hal denota F, Cl, Br o I; m denota 0, 1 ó 2; n denota 0, 1, 2, 3 ó 4; o denota 1, 2 ó 3; excluyendo los compuestos de la fórmula (1) en donde: a) R1 = H, R2 = H; b) R1 = H, R2 = fenetilo; y sus sales, solvatos, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones, para usar en la prevención y/o el tratamiento de cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10005432 | 2010-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081828A1 true AR081828A1 (es) | 2012-10-24 |
Family
ID=44534228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101794A AR081828A1 (es) | 2010-05-26 | 2011-05-26 | Compuestos de biguanida y su uso para el tratamiento del cancer |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130059916A1 (es) |
| EP (1) | EP2575792A1 (es) |
| AR (1) | AR081828A1 (es) |
| WO (1) | WO2011147528A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013188452A1 (en) | 2012-06-11 | 2013-12-19 | The Regents Of The University Of California | Compounds and methods of treating cancer |
| US10119976B2 (en) | 2013-05-28 | 2018-11-06 | Biogen Ma Inc. | Method of assessing risk of PML |
| WO2015026215A1 (ko) * | 2013-08-23 | 2015-02-26 | 가톨릭대학교 산학협력단 | 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물 |
| KR101642587B1 (ko) | 2013-08-23 | 2016-07-25 | 가톨릭대학교 산학협력단 | 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물 |
| KR20170042778A (ko) * | 2014-08-19 | 2017-04-19 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법 |
| CN104230760B (zh) * | 2014-09-02 | 2016-07-06 | 浙江工业大学 | N-芳基取代的双胍氢溴酸盐类化合物及制备方法和应用 |
| KR102216701B1 (ko) * | 2014-11-20 | 2021-02-18 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
| US12415781B2 (en) | 2018-06-05 | 2025-09-16 | Institut Curie | Compounds with biguanidyl radical and uses thereof |
| US11065188B2 (en) * | 2019-05-29 | 2021-07-20 | Av Laboratories Llc | Applications and formulations of optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents |
| CN113354561B (zh) * | 2021-04-17 | 2023-03-28 | 中山大学 | 双胍衍生物及其应用与制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2322860A1 (fr) | 1975-09-05 | 1977-04-01 | Aron Sarl | Procede de preparation de chlorhydrate de dimethylbiguanide |
| CA2183577C (en) | 1994-03-07 | 2007-10-30 | John S. Patton | Methods and compositions for pulmonary delivery of insulin |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| FR2858232B1 (fr) * | 2003-07-29 | 2006-03-03 | Pierre Potier | Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb |
| US20080194019A1 (en) | 2003-09-09 | 2008-08-14 | Beth Israel Deaconess Medical Center, Inc. | Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase |
| CN1846694B (zh) * | 2005-04-12 | 2012-02-01 | 中国医学科学院血液学研究所 | 取代芳香基双胍类化合物及含它们的药物组合物在制备抗恶性肿瘤药物方面的应用 |
| CA2666036C (en) * | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
| KR101083300B1 (ko) * | 2008-10-13 | 2011-11-14 | 한국화학연구원 | Ｎ1-벤조［1,3］다이옥솔-5-일메틸-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
-
2010
- 2010-05-06 US US13/696,347 patent/US20130059916A1/en not_active Abandoned
-
2011
- 2011-05-06 EP EP11718951.4A patent/EP2575792A1/en not_active Withdrawn
- 2011-05-06 WO PCT/EP2011/002268 patent/WO2011147528A1/en not_active Ceased
- 2011-05-26 AR ARP110101794A patent/AR081828A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2575792A1 (en) | 2013-04-10 |
| WO2011147528A1 (en) | 2011-12-01 |
| US20130059916A1 (en) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR090602A1 (es) | AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2 | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| ECSP19026680A (es) | COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING | |
| AR084507A1 (es) | Derivados de indazoliltriazol | |
| AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol | |
| AR092211A1 (es) | Derivados de hidropirrolopirrol | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR082726A1 (es) | Derivados de triazolopirazina | |
| AR082728A1 (es) | Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos | |
| AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| AR052482A1 (es) | Derivados de triazol como inhibidores de hsp90 | |
| AR073055A1 (es) | Derivados biciclicos de triazol | |
| AR061009A1 (es) | 1,2-difenil-pirazoles i i como inhibidores de hsp90 | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR090103A1 (es) | Derivados ciclicos de diaminopirimidina | |
| AR082727A1 (es) | Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR054047A1 (es) | Derivados de fenilquinazolina | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR107738A1 (es) | Amidas de ácido n-(5-halógen-1,3,4-oxadiazol-2-il)arilcarboxílico y su uso como herbicidas | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| AR051135A1 (es) | Fenilpirazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |